CNTX

0.16005.10%
KL

Karen L. Smith

Independent Director

Dr. Karen L. Smith, M.D. PH.D. M.B.A. L.L.M, is Chief Marketing Officer at Myosin Therapeutics Inc. She serves as Chief Medical Officer since October 28, 2025 at Step Pharma SAS. She serves as Member of Adult Heart Failure Clinical Advisory Board of Secretome Therapeutics, Inc. from 2025. Dr. Smith had been a Director of Aurinia Pharmaceuticals Inc. August 2023 until May 2025 and served as its Independent Director from August 18, 2023. She served as Chief Medical Officer at Secretome Therapeutics, Inc. She serves as Independent Director of Context Therapeutics Inc. since September 2024 and also served as Chief Medical Officer Since May 10, 2025 until June 06, 2025. She serves as Independent Director at Skye Bioscience, Inc. from July 2024. She served as Member of Advisory Board of Beaconcure Inc. since October 2023. She serves as Director at Capstan Therapeutics, Inc. She was Independent Director of Talaris Therapeutics, Inc. from June 2022 to October 2023. She was Chief Medical Officer of Quince Therapeutics, Inc. (formerly known as Cortexyme, Inc.) from May 08, 2022 until September 01, 2023. She was Chief Medical Officer at Novosteo Inc. from January 2022 to September 2023. She serves as Independent Director of Mariana Oncology, Inc. (formerly known as Curie Therapeutics, Inc.). since March 2022 and its Independent Board Chair since 2023. She serves as Chairman of Strategic Advisory Board at Emyria Limited since February 2021 and served as its Executive Director since November 29, 2021 and serves as its Non-Executive Director from November 13, 2023. She served as Director at Tourmaline Bio, Inc. She served as Director of Humanetics Corporation since 2021 until 2023 and served as its Member of Board of Advisors since 2023. Dr. Smith served as Chief Medical Officer at Emergent BioSolutions Inc. since April 2020 and serves its Executive Vice President since April 2020. She is Director of Acceleron Pharma Inc. since November 15, 2017 until December 2021. Dr. Smith was Chief Medical Officer and Executive Vice President of R&D at Jazz Pharmaceuticals Public Limited Company from April 2015 and May 2017 to 2018 respectively and was its Global Head of Research and Development since April 2015 until May 2018. Dr. Smith serves as Director at Allergan plc since March 2019. Dr. Smith has overseen numerous trials and regulatory approvals leading to global product launches of small molecules, biologics and devices across oncology and other therapeutic areas. She is an accomplished executive who has led departments within large pharma (Allergan, Astra-Zeneca, Bristol Myers Squibb) and served as CMO or CEO at notable biotech companies (Jazz & ECI). Dr. Smith served as Director at Antares Pharma, Inc. since March 4, 2019 until May 24, 2022. Dr. Smith was also the founding Chief Executive Officer and President of the Minderoo Foundation?s ?Eliminate Cancer Initiative? supported by Andrew Forrest and remains an advisor to that program from June 2018 to May 2019. Dr. Smith is an Advisor to the Chief Executive Officer of Forward Pharma. Dr. Smith served as Senior Vice President, Global Medical Affairs and Global Therapeutic Area Head (Dermatology) for Allergan, Inc. since January 2011 to until 2015. Dr. Smith most recently was President and CEO of Medeor Therapeutics, Inc. since May 2018 until January 2020 and she consulted internationally from May 2018 to April 2020. She served initially as Vice President of External Medical Relations and then Vice President of Global Development at AstraZeneca LP since October 2007 until December 2010. She held a variety of management and medical roles with Bristol-Myers Squibb Company, a global biopharmaceutical company, in Australia, Canada and the United States, as the Head of U.S. Clinical Operations since 2002 until 2007. Since 2001, Dr. Smith served as the Chief Executive Officer of Boron Molecular. Dr. Smith has senior leadership and executive experience with both major pharmaceutical companies and start-up biotechnology organizations in drug development, regulatory, operations and business strategy. Her product development expertise spans various therapeutic areas and includes major drug and device approvals in North and Latin America, Asia, Europe and Australia. Dr. Smith has biopharmaceutical experience bringing drugs into the clinic and through commercialization. She also serves on the Boards of Susan G. Komen (Orange County), Girl Scouts of Orange County and on the Women?s Advisory Board for Ironman Corporation. Dr. Smith was a Director of Sucampo Pharmaceuticals, Inc. since July 15, 2017 until February 2018. Dr. Smith?s credentials include a B.App.Sc. with a double major in Biotechnology and Haematology; an M.D. Dr. Smith has been an Independent Director of Sangamo Therapeutics, Inc. since June 26, 2018. Dr. Smith served as Non-Executive Director at Forward Pharma A/S since May 06, 2016 until May 2017. Dr. Smith holds a B.A.Sc. and a B.Sc. from the Curtin University of Technology, an M.D. in Cardiology from the University of Warwick, a Ph.D. in Molecular oncology and Molecular Genetics from the University of Western Australia & UCLA (USA), a Ph.D. in Oncology from University of California, an M.B.A. from the University of New England (Australia) and an L.L.M. (Masters in Law) in medical law from the University of Salford (U.K.).

Positions